Related Experiment Video
Updated: May 27, 2026

Cigarette Smoke Exposure in Mice using a Whole-Body Inhalation System
Published on: October 22, 2020
The effect of smoking on the symptoms and progression of multiple sclerosis: a review
Afsaneh Shirani1, Helen Tremlett
1Faculty of Medicine, Division of Neurology, University of British Columbia, Vancouver, Canada.
Abstract:
Multiple sclerosis (MS) is a chronic inflammatory neurodegenerative disorder of the central nervous system with characteristic demyelinating lesions and axonal loss. MS accounts for the most common cause of neurological disability in young adults in the Western world. The clinical manifestations and the course of MS are highly variable. The early stage of the disease is usually characterized by attacks of neurological dysfunction with complete or incomplete recovery, however, with time disability accumulates in many patients. MS is believed to result from an interplay between susceptibility genes and environmental factors, one of which is smoking. Smoking, a worldwide epidemic, can be regarded as an important risk factor for MS particularly because of its modifiable nature in the quest to prevent or temper the disease course in MS as well as providing possible insights into MS pathogenesis. There are also reports that smoking may influence the symptoms and disease progression in patients with MS. The purpose of this article is to review the effects of smoking on MS symptoms and progression. We conclude that (1) although there are some early reports on worsening of MS symptoms by smoking, the existing evidence is insufficient to thoroughly assess the effects of smoking on the myriad of MS symptoms and (2) smoking seems to adversely influence disease progression in MS patients. We also discuss the potential biological mechanisms linking smoking and MS.
Insights
Smoking is a significant risk factor for multiple sclerosis (MS), potentially worsening disease progression. While evidence on symptom impact is limited, avoiding smoking may help manage MS.
Area of Science:
- Neuroimmunology
- Neurodegenerative Diseases
- Public Health
Background:
- Multiple sclerosis (MS) is a leading cause of neurological disability in young adults.
- MS involves demyelination and axonal loss in the central nervous system.
- Genetic and environmental factors, including smoking, contribute to MS development.
Purpose of the Study:
- To review the impact of smoking on multiple sclerosis symptoms.
- To examine the influence of smoking on MS disease progression.
- To discuss potential biological mechanisms linking smoking and MS.
Main Methods:
- Literature review of studies on smoking and multiple sclerosis.
- Analysis of evidence regarding smoking's effect on MS symptoms.
- Assessment of smoking's influence on MS disease course and pathogenesis.
Main Results:
- Current evidence is insufficient to definitively assess smoking's effect on diverse MS symptoms.
- Smoking appears to negatively influence disease progression in MS patients.
- Potential biological pathways connecting smoking and MS pathogenesis are discussed.
Conclusions:
- Smoking is a modifiable risk factor for multiple sclerosis.
- Quitting smoking may help temper MS disease progression.
- Further research is needed to fully understand smoking's complex relationship with MS symptoms.
Related Concept Videos
Multiple Sclerosis l: Introduction
Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:
Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features
Stress Prevention and Stress Management Techniques IV
COPD: Pathogenesis and Clinical Features
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
Drugs Acting on Autonomic Ganglia: Stimulants
Ganglionic stimulants activate NM nicotinic receptors in autonomic ganglia, falling into two categories: nicotine mimetics [e.g., lobeline, dimethylpiperazine, tetramethylammonium] and muscarinic receptor agonists [e.g., muscarine, methacholine]. The first category's action is rapid and blocked by nicotinic receptor antagonists, while the second category's action is delayed and blocked by atropine-like agents. Nicotine, an alkaloid, affects the heart rate by stimulating sympathetic or...
